CA3187716A1 - Pharmaceutical composition of aquaporin inhibitor and preparation method thereof - Google Patents
Pharmaceutical composition of aquaporin inhibitor and preparation method thereofInfo
- Publication number
- CA3187716A1 CA3187716A1 CA3187716A CA3187716A CA3187716A1 CA 3187716 A1 CA3187716 A1 CA 3187716A1 CA 3187716 A CA3187716 A CA 3187716A CA 3187716 A CA3187716 A CA 3187716A CA 3187716 A1 CA3187716 A1 CA 3187716A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- bis
- trifluoromethyl
- meglumine
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010779964.6 | 2020-08-05 | ||
| CN202010779964 | 2020-08-05 | ||
| PCT/CN2021/110506 WO2022028459A1 (en) | 2020-08-05 | 2021-08-04 | Pharmaceutical composition of aquaporin inhibitor and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3187716A1 true CA3187716A1 (en) | 2022-02-10 |
Family
ID=80120008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3187716A Pending CA3187716A1 (en) | 2020-08-05 | 2021-08-04 | Pharmaceutical composition of aquaporin inhibitor and preparation method thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230293556A1 (https=) |
| EP (1) | EP4192442A4 (https=) |
| JP (1) | JP2023536509A (https=) |
| KR (1) | KR20230137284A (https=) |
| CN (1) | CN117337182A (https=) |
| AU (1) | AU2021323181A1 (https=) |
| BR (1) | BR112023002129A2 (https=) |
| CA (1) | CA3187716A1 (https=) |
| IL (1) | IL300341A (https=) |
| MX (1) | MX2023001493A (https=) |
| TW (1) | TW202228714A (https=) |
| WO (1) | WO2022028459A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013169939A2 (en) | 2012-05-08 | 2013-11-14 | Aeromics, Llc | New methods |
| US20160279155A1 (en) | 2013-11-06 | 2016-09-29 | Aeromics, Inc. | Novel formulations |
| US11117909B2 (en) | 2016-05-13 | 2021-09-14 | Aeromics, Inc. | Crystals |
| WO2024208207A1 (zh) * | 2023-04-03 | 2024-10-10 | 拜西欧斯（北京）生物技术有限公司 | 一种双取代萘化合物及其药物组合物和用途 |
| WO2025075479A1 (ko) * | 2023-10-04 | 2025-04-10 | 이화여자대학교 산학협력단 | 아쿠아포린 4 억제제의 심방세동 치료 용도 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2488363C (en) * | 2002-06-06 | 2011-01-04 | Institute Of Medicinal Molecular Design, Inc. | O-substituted hydroxyaryl derivatives |
| WO2008067196A2 (en) * | 2006-11-16 | 2008-06-05 | The Regents Of The University Of California | Methods for identifying inhibitors of solute transporters |
| WO2013169939A2 (en) * | 2012-05-08 | 2013-11-14 | Aeromics, Llc | New methods |
| US20160279155A1 (en) * | 2013-11-06 | 2016-09-29 | Aeromics, Inc. | Novel formulations |
| CA2931550C (en) * | 2013-12-13 | 2023-09-26 | Vertex Pharmaceuticals Incorporated | Prodrugs of pyridone amides useful as modulators of sodium channels |
| US11117909B2 (en) * | 2016-05-13 | 2021-09-14 | Aeromics, Inc. | Crystals |
-
2021
- 2021-08-04 EP EP21852147.4A patent/EP4192442A4/en active Pending
- 2021-08-04 AU AU2021323181A patent/AU2021323181A1/en active Pending
- 2021-08-04 US US18/040,618 patent/US20230293556A1/en active Pending
- 2021-08-04 CA CA3187716A patent/CA3187716A1/en active Pending
- 2021-08-04 IL IL300341A patent/IL300341A/en unknown
- 2021-08-04 BR BR112023002129A patent/BR112023002129A2/pt unknown
- 2021-08-04 CN CN202180057413.1A patent/CN117337182A/zh active Pending
- 2021-08-04 JP JP2023508083A patent/JP2023536509A/ja active Pending
- 2021-08-04 WO PCT/CN2021/110506 patent/WO2022028459A1/en not_active Ceased
- 2021-08-04 MX MX2023001493A patent/MX2023001493A/es unknown
- 2021-08-04 KR KR1020237007248A patent/KR20230137284A/ko active Pending
- 2021-08-05 TW TW110128921A patent/TW202228714A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023536509A (ja) | 2023-08-25 |
| CN117337182A (zh) | 2024-01-02 |
| AU2021323181A1 (en) | 2023-03-23 |
| IL300341A (en) | 2023-04-01 |
| MX2023001493A (es) | 2023-06-23 |
| EP4192442A1 (en) | 2023-06-14 |
| BR112023002129A2 (pt) | 2023-04-18 |
| US20230293556A1 (en) | 2023-09-21 |
| TW202228714A (zh) | 2022-08-01 |
| EP4192442A4 (en) | 2025-03-19 |
| KR20230137284A (ko) | 2023-10-04 |
| WO2022028459A1 (en) | 2022-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3187716A1 (en) | Pharmaceutical composition of aquaporin inhibitor and preparation method thereof | |
| EP2676677B1 (en) | Highly concentrated anti-cd40 antibody pharmaceutical preparation | |
| EP4066849B1 (en) | Daptomycin formulations and uses thereof | |
| CA2234140C (fr) | Formulation pharmaceutique lyophilisee stable | |
| HU202761B (en) | Process for producing stabilized erythropoietin compositions | |
| US9168239B2 (en) | Levothyroxine formulations | |
| JP6542888B2 (ja) | カルムスチン医薬組成物 | |
| JP2018531268A (ja) | ダントロレンを含む水性組成物 | |
| JP2018531268A6 (ja) | ダントロレンを含む水性組成物 | |
| JP4142149B2 (ja) | バンコマイシンの凍結乾燥製剤 | |
| SE466383B (sv) | Injicerbar bruksfaerdig antracyklinglykosidloesning samt foerfarande foer dess framstaellning | |
| KR101468153B1 (ko) | 5α-안드로스테인-3β,5,6β-트리올 주사제 및 제조방법 | |
| KR100807650B1 (ko) | Ｎ-[ｏ-(ｐ-피발로일옥시벤젠술포닐아미노)벤조일]글리신·모노나트륨염·4수화물의 동결 건조 제제 및 그 제조 방법 | |
| EP4019033B1 (en) | Injectable solution comprising a spirofused tetrapeptide an a ph-regulator for treating kappa opioid receptor-associated conditions | |
| CN107519136B (zh) | 一种氯化琥珀胆碱冻干制剂及其制备方法 | |
| KR100725076B1 (ko) | Ｎ-[ｏ-(ｐ-피발로일옥시벤젠술포닐아미노)벤조일]글리신·모노나트륨염·4수화물 함유 용액 및 제제 | |
| EP4674418A1 (en) | Solution, freeze-dried formulation, freeze-dried formulation unit package, injection, and injection preparation method | |
| WO2023049346A1 (en) | Bortezomib compositions | |
| WO2017198224A1 (zh) | 一种瑞马唑仑的药物组合物 | |
| RU2803937C2 (ru) | Состав для парентерального введения, содержащий сипонимод | |
| HK40081664B (en) | Daptomycin formulations and uses thereof | |
| HK40081664A (en) | Daptomycin formulations and uses thereof | |
| KR20180086423A (ko) | 다니릭신의 정맥내 투여를 위한 제제 | |
| EA023081B1 (ru) | Инъекционная лекарственная форма флупиртина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240718 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240718 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250728 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250728 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250731 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250731 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251014 Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251014 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20251014 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251015 |